<DOC>
	<DOCNO>NCT02756611</DOCNO>
	<brief_summary>The purpose open-label , single-arm study evaluate efficacy venetoclax monotherapy approximately 250 participant relapsed/refractory CLL include 17p deletion TP53 mutation ( assessed local lab ) OR receive prior treatment B-cell receptor inhibitor . The start dose venetoclax 20 mg daily . The dose must gradually increased period 5 week daily dose 400 mg . Participants may continue receive venetoclax 2 year . After treatment period , participant may continue 2-year follow-up period .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Venetoclax Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia ( CLL ) Including Those With 17p Deletion TP53 Mutation Those Who Have Received Prior B-cell Receptor Inhibitor .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Receptors , Antigen , B-Cell</mesh_term>
	<criteria>Participant Eastern Cooperative Oncology Group ( ECOG ) performance score less equal 2 Participant relapsed/refractory disease ( receive least 1 prior therapy ) Participant diagnosis CLL meet publish 2008 Modified IWCLL NCIWG Guidelines : indication treatment accord 2008 Modified IWCLL NCIWG criterion clinically measurable disease ( lymphocytosis great 5 Ã— 109/L and/or palpable measurable node physical exam and/or organomegaly assess physical exam ) In addition , participant : may harbor 17p deletion TP53 mutation , assess local laboratory bone marrow peripheral blood AND/OR may previously treat prior Bcell receptor inhibitor Participant must adequate bone marrow function , coagulation profile , renal , hepatic function , per laboratory reference range Screening Participant develop Richter 's transformation Prolymphocytic leukemia Participant previously receive venetoclax History active malignancy CLL within past 2 year prior first dose venetoclax , exception : adequately treat situ carcinoma cervix uteri adequately treat basal cell carcinoma localize squamous cell carcinoma skin previous malignancy confine surgically resect ( treated modality ) curative intent Participant active uncontrolled autoimmune cytopenia ( 2 week prior Screening ) , include autoimmune hemolytic anemia idiopathic thrombocytopenic purpura despite low dose corticosteroid Participant undergone allogeneic stem cell transplant grade 2 : Any anticancer therapy include chemotherapy , radiotherapy ; Investigational therapy , include target small molecule agent Participant human immunodeficiency virus ( HIV ) positive Participant know allergy xanthine oxidase inhibitor rasburicase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Oncology</keyword>
	<keyword>TP53 Mutation</keyword>
	<keyword>Refractory</keyword>
	<keyword>Relapsed</keyword>
	<keyword>B-Cell receptor inhibitor</keyword>
	<keyword>17p Deletion</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
</DOC>